CA2637137A1 - Nouvelle methode pour la protection d'ilots de langerhans de l'apoptose au cours du processus de prelevement chez un donneur - Google Patents

Nouvelle methode pour la protection d'ilots de langerhans de l'apoptose au cours du processus de prelevement chez un donneur Download PDF

Info

Publication number
CA2637137A1
CA2637137A1 CA002637137A CA2637137A CA2637137A1 CA 2637137 A1 CA2637137 A1 CA 2637137A1 CA 002637137 A CA002637137 A CA 002637137A CA 2637137 A CA2637137 A CA 2637137A CA 2637137 A1 CA2637137 A1 CA 2637137A1
Authority
CA
Canada
Prior art keywords
eif5a
sirna
islet cells
islet
apoptosis
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
CA002637137A
Other languages
English (en)
Inventor
John E. Thompson
Charles A. Dinarello
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Eloxx Pharmaceuticals Inc
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Individual filed Critical Individual
Publication of CA2637137A1 publication Critical patent/CA2637137A1/fr
Abandoned legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7088—Compounds having three or more nucleosides or nucleotides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0676—Pancreatic cells
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/10—Type of nucleic acid
    • C12N2310/14—Type of nucleic acid interfering N.A.

Landscapes

  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • Biomedical Technology (AREA)
  • Genetics & Genomics (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Biotechnology (AREA)
  • Molecular Biology (AREA)
  • Diabetes (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Immunology (AREA)
  • General Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Microbiology (AREA)
  • Biochemistry (AREA)
  • Endocrinology (AREA)
  • Plant Pathology (AREA)
  • Epidemiology (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Physics & Mathematics (AREA)
  • Biophysics (AREA)
  • Emergency Medicine (AREA)
  • Cell Biology (AREA)
  • Transplantation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
CA002637137A 2006-03-20 2007-03-20 Nouvelle methode pour la protection d'ilots de langerhans de l'apoptose au cours du processus de prelevement chez un donneur Abandoned CA2637137A1 (fr)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US78341406P 2006-03-20 2006-03-20
US60/783,414 2006-03-20
PCT/US2007/064424 WO2007109677A2 (fr) 2006-03-20 2007-03-20 Nouvelle méthode pour la protection d'îlots de langerhans de l'apoptose au cours du processus de prélèvement chez un donneur

Publications (1)

Publication Number Publication Date
CA2637137A1 true CA2637137A1 (fr) 2007-09-27

Family

ID=39680975

Family Applications (1)

Application Number Title Priority Date Filing Date
CA002637137A Abandoned CA2637137A1 (fr) 2006-03-20 2007-03-20 Nouvelle methode pour la protection d'ilots de langerhans de l'apoptose au cours du processus de prelevement chez un donneur

Country Status (7)

Country Link
EP (1) EP1996707A2 (fr)
JP (1) JP5543774B2 (fr)
AR (1) AR060785A1 (fr)
AU (1) AU2007226878A1 (fr)
CA (1) CA2637137A1 (fr)
IL (1) IL192388A0 (fr)
WO (1) WO2007109677A2 (fr)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN102124108A (zh) * 2007-08-20 2011-07-13 森尼斯科技术公司 Eif-5a1 sirna保护胰岛细胞免受凋亡和维持它们功能性的用途

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7166467B2 (en) * 2001-07-23 2007-01-23 Senesco Technologies, Inc. Nucleic acids, polypeptides, compositions, and methods for modulating apoptosis
NZ542665A (en) * 2003-03-05 2008-05-30 Senesco Technologies Inc Use of antisense oligonucleotides or siRNA to suppress expression of eIF-5A1
EP1636364A2 (fr) * 2003-06-06 2006-03-22 Senesco Technologies, Inc. Inhibition d'eif-5a specifique de l'apoptose ("eif-5a1") au moyen d'oligonucleotides antisens et de petits arn interferents utilises comme agents therapeutiques anti-inflammatoires

Also Published As

Publication number Publication date
WO2007109677A2 (fr) 2007-09-27
AU2007226878A1 (en) 2007-09-27
EP1996707A2 (fr) 2008-12-03
IL192388A0 (en) 2008-12-29
WO2007109677A3 (fr) 2008-04-24
JP2009530418A (ja) 2009-08-27
JP5543774B2 (ja) 2014-07-09
AR060785A1 (es) 2008-07-10

Similar Documents

Publication Publication Date Title
Aguiari et al. High glucose induces adipogenic differentiation of muscle-derived stem cells
Guay et al. Emerging roles of non‐coding RNAs in pancreatic β‐cell function and dysfunction
Ye et al. Exosomal circEhmt1 released from hypoxia‐pretreated pericytes regulates high glucose‐induced microvascular dysfunction via the NFIA/NLRP3 pathway
Kriz et al. A novel technique for the transplantation of pancreatic islets within a vascularized device into the greater omentum to achieve insulin independence
JP2008237221A (ja) 圧力媒介による、分子または微小粒子の細胞内への輸送
Balamurugan et al. Harmful delayed effects of exogenous isolation enzymes on isolated human islets: relevance to clinical transplantation
Muthyala et al. The effect of hypoxia on free and encapsulated adult porcine islets—an in vitro study
US10751375B2 (en) Mitochondrial epigenetic reprogramming and transplant
WO2014153620A1 (fr) Procédé de génération de cellules matures de type bêta
CN114432452A (zh) RNA Hsa_circ_0063865抑制剂在制备抗食管鳞状细胞癌药物中的应用
Li et al. Upregulated miR-206 aggravates deep vein thrombosis by regulating GJA1-mediated autophagy of endothelial progenitor cells
CN110157708B (zh) 一种抑制人脑胶质瘤的靶向linc01023基因的抑制剂及其应用
CA2637137A1 (fr) Nouvelle methode pour la protection d'ilots de langerhans de l'apoptose au cours du processus de prelevement chez un donneur
US20080076728A1 (en) Novel method of protecting islet cells from apoptosis during the donor harvesting process
JP2010536379A (ja) アポトーシスから膵島細胞を保護するため、そしてその機能を保持するためのＥＩＦ−５Ａ１のｓｉＲＮＡの使用
AU2013273798A1 (en) A novel method of protecting islet cells from apoptosis during the donor harvesting process
EP2594634B1 (fr) Procédé de séparation d'îlots pancréatiques, et solution de conservation destinée à conserver les tissus d'îlots pancréatiques
CN114191554A (zh) 抑制tert表达的试剂在制备预防或治疗胸主动脉瘤的药物中的应用
TW200839013A (en) A novel method of protecting islet cells from apoptosis during the donor harvesting process
CN111920955A (zh) Grb10作为β细胞功能障碍的关键负调节因子中的应用
Nagaya et al. Effectiveness of bioengineered islet cell sheets for the treatment of diabetes mellitus
CN110257377B (zh) 一种抑制人恶性脑胶质瘤的靶向linc00998基因的抑制剂及其应用
CN112852965B (zh) lnc-ZNF100-5功能性表达抑制剂在制备治疗乳腺癌的药物中的应用
Walker MicroRNAs and Long Non-Coding RNAs in Pancreatic Beta Cell Function
A-Elgadir et al. Mesenchymal stem cells improve cardiac function in diabetic rats by reducing cardiac injury biomarkers and downregulating JAK/STAT/iNOS and iNOS/Apoptosis signaling pathways

Legal Events

Date Code Title Description
EEER Examination request
FZDE Discontinued

Effective date: 20160321